RESEARCH ARTICLE

Genetic variation in Interleukin-32 influence the immune response against New World Leishmania species and susceptibility to American Tegumentary Leishmaniasis

Jéssica Cristina dos Santos1,2☯, Valéria Bernadete Leite Quixabeira2,3☯, Muriel Vilela Teodoro Silva2, Michelle S. M. A. Damen1,4, Kiki Schraa1, Martin Jaeger1, Marije Oosting1, Samuel T. Keating1, Miriam Leandro Dorta5, Sebastião Alves Pinto3,5, Fernanda Bugalho Duarte6, Lecide Inácia de Araújo Pereira4,7, Mihai G. Netea1,8, Fátima Ribeiro-Dias2☯, Leo A. B. Joosten1☯*

1 Radboud Institute for Molecular Sciences (RILMS), Department of Internal Medicine and Radboud Center of Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, The Netherlands, 2 Laboratório de Imunidade Natural (LIN), Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, Goiás, Brazil, 3 Instituto Goiano de Oncologia e Hematologia (INGOH), Goiânia, Goiás, Brazil, 4 Division of Immunobiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States of America, 5 Faculdade de Medicina, Universidade Federal de Goiás, Goiânia, Goiás, Brazil, 6 Hospital Unique, Goiás, Brazil, 7 Hospital de Doenças Tropicais Anuar Auad, Goiânia, Goiás, Brazil, 8 Department for Genomics & Immunoregulation, Life and Medical Sciences Institute (LIMES), University of Bonn, Bonn, Germany

☯ These authors contributed equally to this work.
* fatimardias@gmail.com (FRD); teo.joosten@radboudumc.nl (LABJ)

Abstract

Interleukin-32 is a novel inflammatory mediator that has been described to be important in the immunopathogenesis and control of infections caused by Leishmania parasites. By performing experiments with primary human cells in vitro, we demonstrate that the expression of IL-32 isoforms is dependent on the time exposed to L. amazonensis and L. braziliensis antigens. Moreover, for the first time we show the functional consequences of three different genetic variations in the IL32 (rs4786370, rs4349147, rs1555001) modulating IL-32γ expression, influencing innate and adaptive cytokine production after Leishmania exposure. Using a Brazilian cohort of 107 American Tegumentary Leishmaniasis patients and a control cohort of 245 healthy individuals, the IL32 rs4786370 genetic variant was associated with protection against ATL, whereas the IL32 rs4349147 was associated with susceptibility to the development of localized cutaneous and mucosal leishmaniasis. These novel insights may help improve therapeutic strategies and lead to benefits for patients suffering from Leishmania infections.

Author summary

In this study, we described how IL-32 isoforms are crucial to host defense against new world Leishmania species infections. Furthermore, by accessing the genotype frequency of
genetic variations in IL-32 in a cohort of Brazilian patients with American Tegumentary Leishmaniasis (ATL) and controls, we have obtained indications that IL-32 is associated with disease susceptibility and the development of different clinical manifestations. Thus, this study provides us an extra evidence that the isoforms of IL-32 shape the immune response favoring the development of different cytokines produced by peripheral blood mononuclear cells that might contribute to skin/mucosal inflammation and host defense.

Introduction

American Tegumentary Leishmaniasis (ATL) is a chronic inflammatory disease caused by protozoa of the genus *Leishmania*. In Brazil, it is caused by species that belong to *Leishmania* (*Viannia*) and *Leishmania* (*Leishmania*) subgenus, which can lead to different clinical manifestations. The localized cutaneous leishmaniasis (LCL) is one of the most frequent and mild forms of disease, which can cure spontaneously in a minority of the leishmaniasis infected patients. However, the other forms of ATL including mucosal leishmaniasis (ML), disseminated leishmaniasis (DL), and diffuse cutaneous lesions (DCL) are more difficult to treat, and relapses are highly frequent [1,2].

Importantly, the clinical manifestation of leishmaniasis is dependent upon both the parasite species and the host’s immune response. For example, *Leishmania* (*V*.) *braziliensis* and *Leishmania* (*L.*) *amazonensis* primarily cause LCL, which is characterized by one or few ulcers in the skin with elevated borders, appearing mainly in exposed areas, like upper limbs, lower limbs and face. Among the severe cases, *L. braziliensis* causes ML affecting primarily the nasopharyngeal and oral mucosal epithelial barriers, often leading to ulceration and septum perforation. DL is characterized by more than ten papular and ulcerated lesions spread on at least two non-contiguous areas of the patient’s body [3,4]. DCL is a rare but severe form of the disease caused by *L. amazonensis* characterized by the presence of non-ulcerative disseminated nodules that often affects face, limbs and trunk of patients [5,6].

Upon inoculation of *Leishmania* spp. by a sand fly into the host skin, cellular and molecular events can influence the development of the disease. Innate immune cells are important during early stages of infection. Dendritic cells (DC), natural killer (NK) cells, neutrophils, and macrophages are fundamental for the host response to the parasite [7,8]. Additionally, pattern recognition receptors (PRR) are critical for *Leishmania* parasite recognition by host immune cells. The major pathogen associated molecular pattern (PAMP) in *Leishmania* is lipophosphoglycan (LPG) [9]. In case of *L. braziliensis* [10] and *L. amazonensis* [11], their LPG can be recognized by Toll-like receptor (TLR) 2 and TLR4, respectively. Toll-like receptors (TLRs), C-type lectin receptors (CLR) dectin-1 and mannose receptor (MR), complement receptors CR1 and CR3, Fc receptors and NOD-like receptor (NLR) have been reported as important for *Leishmania*-host interface [12–14].

In addition to its well-described function in parasite control, IFNγ has been associated with immunopathology in ATL. Furthermore, TNFα, IL-1β, IL-17 and CD8+ T lymphocytes have also been implicated in promoting pathology in leishmaniasis. [15–18]. Contrary to inflammatory cytokines, IL-10 can regulate some of these immunopathologic responses [19,20]. Moreover, other members of the IL-10 family have been identified as key players in the wound healing process [21,22]. IL-22 is one of the members of this family, which has been pointed as an important factor to limit *Leishmania*-induced immunopathology [23].

IL-32 is another cytokine that has been described to be involved in the immunopathogenesis of inflammatory diseases and control of intracellular pathogens. IL-32 is mainly produced...
IL-32 influences host defense against Leishmania species

by immune cells, but it is additionally expressed in non-immune cells including epithelial and endothelial cells [24–28]. IL-32 mRNA can be processed by alternative splicing, generating several different isoforms. The isoforms are generated from the pre-mRNA for IL-32γ, which in respect to inflammation is the most active isoform. In the context of human diseases, the most studied isoforms are IL-32α, IL-32β and IL-32γ [29,30]. On the functional level, IL-32γ amplifies inflammatory signaling induced by TNFα and synergizes with PRRs for the induction of IL-1β and IL-6 [31,32]. Through these mechanisms, IL-32 drives innate immune cells to generate Th1 and Th17 cellular responses [33]. Furthermore, IL-32γ inhibits Hepatitis B virus activities at the transcriptional level through a non-cytokine function in hepatocytes [34].

We previously described the expression of IL-32 in epithelial, endothelial and mononuclear cells in lesions from patients with LCL and ML [35]. In fact, IL-32 has also been implicated as a key player in controlling parasite load in infections caused by L. braziliensis or L. amazonensis in both the IL-32γ-transgenic mouse model and human cells [36,37]. To date, it is not precisely known how IL-32 isoforms contribute to host defense against Leishmania infections. In the current study, we confirmed that IL32 mRNA and protein are expressed in human PBMCs stimulated with L. amazonensis or L. braziliensis. We further evaluated the functional consequences of three different genetic variations in IL32 (rs4786370, rs4349147, rs1555001) for innate and adaptive cytokine production. Furthermore, by analyzing a cohort of 107 ATL patients and 245 controls, we evaluated whether these genetic variations in IL32 influence the susceptibility to disease and the clinical outcome. Finally, the expression of important inflammatory mediators in lesion fragments from ATL patients was correlated with mRNA levels of IL-32 isoforms.

Materials and methods

Patients, controls and tissues samples

The Brazilian cohort of ATL patients: to access genetic variations, ATL patients (n = 107) were asked to provide blood. All patients were diagnosed with cutaneous (n = 68), mucosal (n = 38) or diffuse (n = 1) ATL in Annuar Auad Tropical Disease Hospital, in Goiânia, Goiás, West Central region of Brazil. To be included in the study, besides a leishmaniasis lesion, patients had at least one exam indicating the presence of parasites were included. Among the technical procedures used for the diagnosis, polymerase chain reaction (PCR) for Leishmania genus, histopathological exam with immunohistochemistry for amastigotes forms (IHC), indirect immunofluorescence (IFI), and Montenegro’s skin test (MST) were used (Table 1) [38]. For cytokine expression evaluation, fragments of cutaneous and mucosal lesions of 56 ATL patients were obtained. All the fragments were tested for parasite DNA using a polymerase chain reaction (PCR-RFLP) described by [39], and presented positive result for Leishmania Viannia subgenus. For gene expression evaluation, one lesion fragment was stored in TRizol reagent (Invitrogen, USA). For the controls (n = 245), blood from healthy individuals was obtained at the blood bank of the Goiano Institute of Oncology and Hematology (INGOH), in Goiânia, Goiás. All procedures were approved by Ethics Committee of Hospital das Clínicas and Hospital Anuar Auad (CAE 47895015.0.0000.5078) and of Federal University of Goiás (n. 164/08), Goiânia, Goiás, Brazil and informed consent was signed by all patients and controls. An additional study was performed using venous blood obtained from 3 Crohn’s disease patients bearing the NOD2 3020insC mutation, blood of 6 healthy individuals was used as control. All human subjects of the study were adults.
IL-32 influences host defense against Leishmania species

Leishmania cultures and lysates

*L. amazonensis* (IFLA/BR/67/PH8) reference strain and MHOM/BR/2003/IMG *L. braziliensis*, a strain from *Leishbank* IPTSP/UFG, were used. Promastigote forms were cultured in Grace’s insect medium (Gibco, Life Technologies, USA) supplemented with 20% of heat-inactivated fetal bovine serum (FBS, Gibco), 100 U/mL of penicillin/streptomycin (Sigma-Aldrich), at 26˚C. Stationary-phase parasites were obtained on the 6th day of growth and washed three times with phosphate-buffered saline (PBS; 1000 x g, 10 min 10˚C). Parasite lysates were obtained by 5 freeze-thaw cycles of promastigotes in the presence of protease inhibitors (Protease inhibitor cocktail, Sigma-Aldrich), in liquid nitrogen followed by thawing in a water bath at 37˚C. Protein quantification was performed using the Pierce BCA protein assay kit (ThermoFisher Scientific, USA).

Isolation of peripheral blood mononuclear cells (PBMC) from healthy controls and treatments

Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats obtained after informed consent of healthy volunteers (Sanquin BloodBank, Nijmegen) and from EDTA tubes of homozygous individuals for the *NOD2* 3020insC mutation, presenting Crohn’s disease. PBMCs were obtained by Ficoll-Paque density gradient cell isolation (GE healthcare, UK), as previously described [12,40]. Cells were resuspended in RPMI 1640 culture medium (Roswell Park Memorial Institute medium; Invitrogen, USA) supplemented with 50 μg/mL gentamicin, 2 mM glutamax (Gibco), and 1 mM pyruvate (Gibco) and quantified. In brief, PBMC stimulations with lysates of both *L. amazonensis* or *L. braziliensis* (50 μg/mL) were performed with 5 x 10^5 cells/well in round-bottom 96-wells plates for either 24 h or 7 days in the presence of culture medium with 10% human pool serum at 37˚C and 5% CO₂.

### Table 1.

| Characteristics of ATL patients | LCL | ML | DL |
|---------------------------------|-----|----|----|
| Male                            | 53/68 | 26/38 | - |
| Female                          | 15/68 | (12/38) | 1 ± 0 |
| Age (Years)                     | 43.7 ± 14.2 | 56.4 ± 15.0 | 41 ± 0 |
| Number of lesions               | 2.0 ± 1.7 | - | 20 ± 0 |
| MST (mm)²                      | 11.6 ± 6.7 | 25.2 ± 15.7 | - |

Positive diagnostic test results % (positive/total tested)

| Test | Positive diagnostic test results |
|------|----------------------------------|
| PCR  | 80.9 (17/21)                     |
| IHC  | 75.0 (33/44)                     |
| IFI  | 62.0 (18/29)                     |
| MST  | 48.3 (15/31)                     |

*One hundred and seven ATL patients who were assisted at Hospital de Doenças Tropicais Anuar Auad (Goiânia—Goiás, West Central, Brazil), 68 with LCL (Localized Cutaneous Leishmaniasis), 38 with ML (Mucosal leishmaniasis) and 1 with DL (Disseminated Leishmaniasis).*

*PCR: polymerase chain reaction for Leishmania genus
IHC: histopathological exam with immunohistochemistry for amastigotes
MST: Montenegro skin test
IFI: indirect immunofluorescence; 72 patients were from West Central region of Brazil (including 25 with ML and 1 with DL); 16 from North (including 4 with ML) and 1 from North East; For remaining 18 patients the data was missing.

https://doi.org/10.1371/journal.pntd.0008029.t001
PBMCs were stimulated during 24 h with LPG (10 μg/mL) from *L. amazonensis* or *L. braziliensis*. In some experiments, PBMCs were pre-incubated for 1 h, at 37˚C, and 5% CO₂ with either *Bartonella quintana* LPS (5 μg/mL) [40] for TLR4 blocking or with laminarin (100 μg/mL; Sigma-Aldrich) as antagonist of Dectin-1. After the stimulation period, supernatants and cells were stored in either 200 μL of TRIzol (Invitrogen) at -80˚C until RNA extraction or in 100 μL of 0.5% TritonX-100 (Sigma-Aldrich) for intracellular IL-32 measurement.

**Genetic analysis in the 200FG cohort**

Genetic variation was assessed in the *IL-32* gene in healthy individuals of Western European descent from the 200FG cohort [41], (http://www.humanfunctionalgenomics.org/). The volunteers were between 23 and 73 years old and consisted of 77% males and 23% females. PBMCs were isolated as described above. After 24 h and 7 days, supernatants were collected and cytokines were measured by enzyme-linked immunosorbent assay (ELISA) as described below.

**Transcriptional analysis**

Previously published microarray data of normal skin samples (n = 10), early (n = 8) and late (n = 17) LCL lesion samples were obtained from the publicly available National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) database (accession number GSE55664) [42]. The expression of selected genes in normal skin versus *L. braziliensis* lesions were represented in a heatmap presented as dendograms shown as a tree, representing the distance between variables. Unsupervised hierarchical clustering of selected genes was performed using the R package hclust with Spearman correlation and presented using the R package ‘corrplot’.

**Quantitative PCR**

RNA was isolated from PBMCs and ATL patient’s lesions stored in TRIzol as previously described [43]. cDNA was made using the iScript kit (Bio-Rad). Primer pairs for the *IL32* isoforms are described elsewhere [36]. *IL1B, IL1A, IL22, IL-17 and IFNG* primers sequences were designed specifically for each transcript using Primer Express 3.0 software (DeNovo Software, Glendale, CA, USA). Primers were produced by Sigma-Aldrich. Diluted cDNA was used for qPCR that was done by using the StepOnePlus qPCR system (Applied Biosystems, Foster City, CA, USA) with SYBR Green Mastermix (Applied Biosystems). Fold change and relative expression were calculated with the 2^ΔΔCT and 2^-dCT methods, respectively and normalized against the housekeeping gene *B2M*.

**Enzyme-linked immunosorbent assay (ELISA)**

Cytokine production was determined in 24 h supernatants using commercial ELISA kits (R&D Systems) for human TNFα, IL-6 and IL-1β. Supernatants of the 7 days stimulation were used to measure IFNγ, IL-17A and IL-22. *IL-32* was determined intracellularly in Triton X-100-cell lysates after 24 h and 7 days using commercial ELISA kit (R&D Systems).

**Isolation of genomic DNA and genetic assessment of *IL32* variations in ATL patients and controls**

DNA was isolated from venous blood of ATL patients and healthy controls using the illustra blood genomicPrep Mini Spin Kit (GE Healthcare, Little Chalfont, UK), according to the manufacturer’s protocol. SNPs in *IL32* were selected based on previously published functional
effects on protein function and/or gene expression and characteristics are described in detail in Supplementary Table 1 [44,45]. Genotyping of ATL patients and controls was performed by TaqMan SNP assays (S1 Table) (Applied Biosystems), according to the manufacturer’s protocol on the StepOnePlus qPCR system (Applied Biosystems). Quality control was performed by the incorporation of positive and negative controls and duplication of random samples across different plates.

**Statistical analysis**

All statistical analyses and graphs of cytokine concentrations and mRNA expression in the *in vitro* PBMC stimulation assays were performed and created using GraphPad Prism 6.00 software (GraphPad Software, San Diego, CA, USA). Data are shown as mean ± SEM. Results were stratified by genotype, and differences in cytokine production between genotypes were analyzed by Mann–Whitney U test, otherwise in each figure, the applied statistical test is indicated in the figure legend. The difference in genotype frequencies between the patients and the control group was analyzed in a dominant and a recessive model using logistic regression. No correction for multiple testing was performed. The effect of the genotypes on ATL susceptibility was estimated by calculating odds ratios (ORs) and their 95% confidence intervals using the same statistical methods. We also performed Fisher test analysis to determine whether clinical manifestations of ATL were associated with one of the *IL32* genotypes. Analyses were conducted using the statistical computing environment, R (v3.5.0). Overall, statistical tests *P*-values of *< 0.05* were considered to be statistically significant.

**Results**

**Differential IL-32 isoform expression is dependent on duration of exposure to *Leishmania* antigens**

To investigate whether *Leishmania* species can induce different isoforms of *IL32* in PBMCs from healthy individuals in a time-dependent manner, we evaluated *IL32* mRNA expression. Both *L. amazonensis* and *L. braziliensis* induced IL-32γ and IL-32β expression in PBMCs after incubation for 24 h (Fig 1A and 1B). On the other hand, after 7 days of *Leishmania*-antigen stimulation, the IL-32β and IL-32α were the main isoforms expressed (Fig 1C and 1D). The production of intracellular IL-32 protein by PBMCs upon exposure to antigens from both *Leishmania* species was enhanced compared to unstimulated cells at both time points (Fig 1E and 1F). However, we observed a 5-fold increase in intracellular IL-32 between 7 days (Fig 1F) and 24 h of incubation (Fig 1E).

**Early induction of IL-32γ is mediated by NOD2, TLR4 and Dectin-1**

In order to evaluate which are the receptors involved in early IL-32 induction by *Leishmania* spp. in PBMCs, we further assessed whether genetic variations in PRRs could affect the expression of IL-32γ expression. Supplemental Fig 1A (S1A Fig) shows a reduction of IL-32γ mRNA expression in PBMCs isolated from individuals carrying a frame shift mutation in the NOD2 receptor (rs2066847-leu1007insC), when compared to individuals carrying no mutation (Wt) after 24 h of exposure to *L. amazonensis* antigens. Exploring TLR2 and TLR4, we observed that a missense SNP in *TLR4* (rs4986791), but not in TLR2 (rs5743708), modulates IL-32γ mRNA expression upon *L. amazonensis* exposure. In addition, we investigated the role of C-type lectin receptors, more specifically Dectin-1 (*CLEC7A* rs16910526 SNP) and Mannose receptor (*CD206* rs1926736 SNP) role in IL-32γ induction. S1B Fig (S1B Fig) shows that a nonsense SNP in *CLEC7A* might influence IL-32γ mRNA expression, since one individual carrying the
CC genotype presented lower IL-32γ mRNA expression compared to individuals bearing AA and AC genotypes. This effect was seen for both species of *Leishmania*. No effect on IL-32γ mRNA expression was observed for individuals carrying different genotypes for a missense SNP in *CD206* (rs1926736).

The influence of NOD2, TLR4 and Dectin-1 signaling on IL-32γ induction upon *Leishmania* spp. exposure was further validated using biological assays. PBMCs isolated from patients carrying a frameshift mutation in NOD2 expressed lower levels of IL-32γ mRNA than...
healthy individuals after *L. amazonensis* stimulation. There were no differences in *L. braziliensis*-stimulated cells (Fig 2A). In addition, when TLR4 was blocked with *Bartonella quintana* LPS (TLR4 antagonist [40]) there was a significant reduction in *Leishmania* spp.-induced IL-32γ mRNA expression (Fig 2B). Next, using laminarin as a Dectin-1 antagonist, we observed a significant reduction in IL-32γ mRNA expression after exposure to both species of *Leishmania* (Fig 2C).
Genetic variations in *IL-32* gene influence cytokine production upon *Leishmania* exposure

To further investigate the relevance of IL-32 for *Leishmania*-induced cytokine production, we used functional genomics searching for SNPs within *IL32* that alter gene expression. Therefore, we assessed the response of PBMCs isolated from 200 healthy volunteers (200FG cohort) stimulated with *L. amazonensis* or *L. braziliensis*. Fig 3A showed that a CC genotype of the

---

**Fig 3.** PBMCs from healthy donors from the 200FG cohort were stimulated with lysates (50 μg/mL) of *L. amazonensis* and *L. braziliensis* for 24 hours. The individuals were stratified according with different genotypes of (A) *IL-32* rs4786370 (TT/CT n = 58; CC n = 7), (B) rs4349147 (GG/GA n = 39; AA n = 4) and (C) rs1555001 (TT/AT n = 57; AA n = 8) and *IL-32γ* gene expression was determined. Results are compiled from at least two independent experiments. The data shown are the mean ± SEM of fold change in *IL-32γ* expression induced by *Leishmania* spp. compared to RPMI control.

https://doi.org/10.1371/journal.pntd.0008029.g003
promoter SNP (rs4786370) trends to have higher mRNA IL-32γ expression after L. amazonensis exposure compared to the TT/CT genotypes (p = 0.057). No major differences were observed after L. braziliensis stimulation. In addition, the effect of a SNP (rs4349147) located in a distal regulatory (enhancer) region of IL32 was examined. Fig 3B showed that individuals bearing the AA genotypes trends to lower levels of L. amazonensis-induced IL-32γ mRNA than those bearing GG/GA genotypes (p = 0.08). Again, no differences were observed for L. braziliensis. In addition, the effect of an intronic SNP (rs1555001) on IL32 gene expression was investigated. Once again, although no significant differences were observed (p > 0.05), the AA genotypes trends to lower IL-32γ mRNA expression compared to the TT/AT genotypes after exposure to both Leishmania species (Fig 3C).

Since genetic variation in the IL32 gene modulates IL32γ expression, we investigated whether these genetic variations influence both innate and adaptive cytokine production in human PBMCs cultured in the presence of L. amazonensis or L. braziliensis antigens. Therefore, we analyzed PBMCs isolated from healthy volunteers of the 200FG cohort with or without those SNPs in the IL32 gene. The classical innate cytokines TNFα, IL-6 and IL-1β were evaluated after 24 h of PBMC stimulation (early IL-32γ production). No significant differences were observed in any of the examined cytokines within the genotypes of the IL-32 promoter SNP after both Leishmania spp. exposure (Fig 4A). In contrast, a lower TNFα, IL-6 and IL-1β production was observed in the group of individuals with the AA genotypes of the enhancer SNP in IL-32 than in PBMCs from individuals bearing the GG/GA genotypes after L. amazonensis stimulation. Moreover, for L. braziliensis antigen stimulation, a reduction in IL-1β production was observed in cells from individuals carrying the AA genotype of the same SNP compared to the GG/GA genotypes. No significant differences were observed in L. braziliensis-induced TNFα and IL-6 production (Fig 4B).

For the intronic SNP of IL32, significant lower TNFα and IL-1β production was observed in the PBMC cultures of individuals carrying the AA genotype than in those of individuals bearing TT/AT genotypes after stimulation with either species of Leishmania. No differences in IL-6 production were observed between the genotypes (Fig 4C). Subsequently, production of the lymphocyte-derived cytokines IFNγ, IL-17 and IL-22 were determined after 7 days of PBMC cultures with Leishmania antigens. Fig 5A shows a higher IL-22 production in the cultures of PBMCs from individuals with CC genotype than those with TT/CT genotypes of the IL-32 promoter SNP (rs4786370) after L. amazonensis stimulation. No differences were observed neither in IFNγ nor in IL-17 production when comparing these genotypes. In addition, for the enhancer SNP (rs4349147), IL-22 production was lower in the AA genotype than the GG/GA genotypes after exposure to both Leishmania species (Fig 5B). In line with previous SNP data, no differences were observed in IFNγ neither in IL-17 production. Interestingly, for the intronic SNP (rs1555001), the production of IFNγ, IL-17 and IL-22 was lower in the cells with AA genotype, which is associated with low levels of IL-32γ expression after L. amazonensis stimulation (Fig 5C). Similar results were noted not for IFNγ and IL-22 production when PBMCs were stimulated with L. braziliensis. Strikingly, L. braziliensis was not capable to induce IL-17 production in the PBMC cultures, in contrast to L. amazonensis (Fig 5).

**Association of IL-32 genetic variations with susceptibility to Leishmania infection**

The observation that IL-32 is induced in PBMCs upon stimulation with Leishmania spp. and that genetic variations in the IL32 gene affect IL-32γ expression, and thereby the production of proinflammatory cytokines, led us to the hypothesis that IL32 SNPs could affect susceptibility to ATL. A Brazilian cohort of 107 ATL patients and a control cohort of 245 healthy individuals...
Fig 4. PBMCs from healthy donors from the 200FG cohort were stimulated with lysates (50 μg/mL) of *L. amazonensis* and *L. braziliensis* for 24 hours. Cytokine levels of TNFα, IL-6 and IL-1β were measured. Cytokine levels were stratified for the different genotypes for (A) IL-32 rs4786370 (TT/CT n = 139; CC n = 25), (B) rs4349147 (GG/GA n = 140; AA n = 23), (C) rs1555001 (TT/AT n = 146; AA n = 17). Dotted line represents the basal level of cytokine production in the RPMI control. The data shown are the mean ± SEM, *p* < 0.05 (TT/CT vs CC; GG/GA vs AA; TT/AT vs AA, respectively, Mann-Whitney U test).

https://doi.org/10.1371/journal.pntd.0008029.g004
Fig 5. PBMCs from healthy donors from the 200FG cohort were stimulated with lysates (50 μg/mL) of *L. amazonensis* and *L. braziliensis* for 7 days. Levels of IFNγ, IL-17 and IL-22 were measured by ELISA. Cytokine levels were stratified for the different genotypes for (A) *IL-32* rs4786370 (TT/CT n = 139; CC n = 25), (B) rs4349147 (GG/GA n = 140; AA n = 23), (C) rs1555001 (TT/AT n = 146; AA n = 17). Dotted line represents the basal level of cytokine production in the RPMI control. The data shown are the mean ± SEM, *p* < 0.05 (TT/CT vs CC; GG/GA vs AA; TT/AT vs AA, respectively, Mann-Whitney U test).

https://doi.org/10.1371/journal.pntd.0008029.g005
were genotyped for *IL32* rs4786370 and rs1555001 genetic variations (Table 2). Different models of genetic variations were tested, including comparison of frequencies of all three genotypes, a dominant model (comparison of frequencies between homozygous wild-type versus

**Table 2.**

| Genotype | Patients (%) | Controls (%) | Odds ratio (95% confidence interval) | P-value |
|----------|--------------|--------------|--------------------------------------|---------|
| rs4786370 |              |              |                                      |         |
| TT       | 37 (35%)     | 82 (34%)     | 1.00 (Reference)                     |         |
| CT       | 60 (56%)     | 108 (44%)    | 1.23 (0.72–2.10)                     | 0.44*   |
| CC       | 10 (9%)      | 55 (22%)     | 0.40 (0.16–0.91)                     | 0.02*   |
| Total    | 107          | 245          |                                      |         |
| Dominant model |          |              |                                      |         |
| TT       | 37 (35%)     | 82 (34%)     | 0.95 (0.58–1.53)                     | 0.83b   |
| CT + CC  | 70 (65%)     | 163 (66%)    |                                      |         |
| Total    | 107          | 245          |                                      |         |
| Recessive model |        |              |                                      |         |
| CC       | 10 (9%)      | 55 (22%)     | 0.35 (0.17–0.72)                     | 4.00E-03b |
| CT + TT  | 97 (91%)     | 190 (78%)    |                                      |         |
| Total    | 107          | 245          |                                      |         |
| rs1555001 |              |              |                                      |         |
| TT       | 51 (48%)     | 132 (53%)    | 1.00 (Reference)                     |         |
| AT       | 49 (46%)     | 96 (39%)     | 1.31 (0.80–2.17)                     | 0.27a   |
| AA       | 7 (6%)       | 20 (8%)      | 0.90 (0.30–2.40)                     | 1*      |
| Total    | 107          | 248          |                                      |         |
| Dominant model |        |              |                                      |         |
| TT       | 51 (48%)     | 132 (53%)    | 1.24 (0.79–1.96)                     | 0.33b   |
| AT + AA  | 56 (52%)     | 116 (47%)    |                                      |         |
| Total    | 107          | 248          |                                      |         |
| Recessive model |        |              |                                      |         |
| AA       | 7 (6%)       | 20 (8%)      | 0.79 (0.32–1.94)                     | 0.62b   |
| AT + TT  | 100 (94%)    | 228 (92%)    |                                      |         |
| Total    | 107          | 248          |                                      |         |
| rs4349147 |              |              |                                      |         |
| GG       | 57 (54%)     | 97 (49%)     | 1.00 (Reference)                     |         |
| GA       | 41 (39%)     | 79 (39%)     | 1.13 (0.66–1.92)                     | 0.70a   |
| AA       | 7 (7%)       | 24 (12%)     | 2.0 (0.77–5.87)                      | 0.14*   |
| Total    | 105          | 200          |                                      |         |
| Dominant model |        |              |                                      |         |
| GG       | 57 (54%)     | 97 (49%)     | 0.79 (0.49–1.27)                     | 0.33b   |
| GA + AA  | 48 (46%)     | 103 (51%)    |                                      |         |
| Total    | 105          | 200          |                                      |         |
| Recessive model |        |              |                                      |         |
| AA       | 7 (7%)       | 24 (12%)     | 0.52 (0.21–1.25)                     | 0.14b   |
| GA + GG  | 98 (93%)     | 176 (88%)    |                                      |         |
| Total    | 105          | 200          |                                      |         |

* Fisher test

**Logistic regression.**

[https://doi.org/10.1371/journal.pntd.0008029.t002](https://doi.org/10.1371/journal.pntd.0008029.t002)
heterozygous + homozygous for the allelic variant), and a recessive model (comparison of frequencies between homozygous wild-type + heterozygous versus homozygous for the allelic variant). For the IL32 rs4786370 variant, the frequency of the CC genotype was significantly higher in controls than in patients (P = 0.02). No differences within genotype frequencies were observed for the IL32 rs1555001 variant between patients and controls (Table 2). Dominant model analyses resulted in no significant different distribution for the IL32 rs4786370 variant. However, when a recessive model was assumed (CC versus CT + TT), significant difference was observed in the distribution of the homozygous for the variant allele in patients and controls, where patients were less often homozygous (CC) than controls. These results pointed towards an increased frequency of the variant in the cohort of controls, arguing for a decreased risk to develop ATL in the presence of homozygous CC genotype (P = 4.00E-03, OR = 0.35 [95% CI, 0.17–0.72]). No significant associations with susceptibility for both dominant and recessive model analysis were observed in patients and controls carrying both IL-32 rs1555001 and IL-32 rs4349147 variations (Table 2).

Association between IL32 genetic variations and ATL clinical manifestations

To assess whether the IL32 genetic variation influences clinical manifestations of ATL, patients were stratified according to the clinical forms, including LCL, ML and DL and compared among the different IL32 genotypes. No statistically significant differences were observed within the frequencies of the genotypes for either IL-32 rs4786370 and rs1555001 variations and the clinical outcome of the patients (Table 3). However, a significant association was observed for the IL-32 rs4349147 genotypes, with the G allele overrepresented in the group of patients with LCL, whereas the A allele is overrepresented in the group of ML patients (P = 0.002). These results suggest that the A allele is associated with susceptibility to develop the more severe form of the disease.

IL-32γ expression is strongly associated with proinflammatory cytokines in ATL skin lesions

To unravel whether IL32 expression in skin lesions of LCL patients is associated to genes linked to skin inflammation and host defense, we analyzed the gene expression profile of

Table 3.

| Summary of genotype–phenotype association within the ATL patient group |
|-----------------------------|----------------|----------------|-------------|-------------|
| rs4786370                   |                |                |             |             |
|                            | TT (%)         | CT (%)         | CC (%)      | Total       | P-value     |
| LCL                         | 23 (61%)       | 39 (66%)       | 6 (60%)     | 68          | 0.33a       |
| ML                          | 15 (39%)       | 20 (34%)       | 3 (30%)     | 38          |             |
| DL                          | 0 (0%)         | 0              | 1 (10%)     | 1           |             |
| rs1555001                   |                |                |             |             |
|                            | TT (%)         | AT (%)         | AA (%)      |             |             |
| LCL                         | 35 (67%)       | 29 (60%)       | 4 (57%)     | 68          | 0.71a       |
| ML                          | 16 (31%)       | 19 (40%)       | 3 (43%)     | 38          |             |
| DL                          | 1 (2%)         | 0 (0%)         | 0 (0%)      | 1           |             |
| rs4349147                   |                |                |             |             |
|                            | GG (%)         | GA (%)         | AA (%)      |             |             |
| LCL                         | 35 (61%)       | 27 (68%)       | 3 (43%)     | 65          | 0.002a      |
| ML                          | 21 (37%)       | 13 (32%)       | 4 (57%)     | 38          |             |
| DL                          | 1 (2%)         | 0 (0%)         | 0 (0%)      | 1           |             |

* Calculated by Fisher test.
IL-32 influences host defense against Leishmania species

L. braziliensis infected skin in comparison to normal skin. The mRNA of the proinflammatory cytokines IL-32, TNF, IL1A, IL1B, IFNG, IL-17A and IL-22, the chemokines CXCL1, CXCL5, CXCL9, as well as the metalloproteinases MMP25, MMP9, MMP10, MMP3 and immune receptors TLR4, TLR2, NOD1, NOD2, ITGA6, CLEC7A, MRC1 were mainly expressed in L. braziliensis lesions [42] (Fig 6A). Next, we evaluated whether all these genes were correlated to each other in LCL skin lesions (Fig 6B, blue: positive; red: negative correlations). A strong positive correlation was observed between functionally related genes, such as IL32 and IL22, which is adjacent to another cluster of CLEC4E, IL6, IL1RN, IL1A, MMP10, MMP9 genes which are also positively correlated.

Since we demonstrate that genetic variations in IL32 influence proinflammatory cytokine production in PBMCs stimulated with Leishmania spp. (Figs 4 and 5), we were prompted to validate whether IL-32γ expression is associated with innate (IL1B, IL1A) and adaptive cytokines (IFNG, IL17 and IL22) in lesion fragments of our cohort of ATL patients. A significantly positive correlation between IL-32γ expression and IL1A (Fig 6D), IFNG, and IL17 (Fig 6E and 6F) was apparent. Of great relevance for host defense, a strong correlation was found between IL-32γ and IL22 (r² = 0.8930, p < 0.0001) (Fig 6C) expressions in ATL lesions. Remarkably, no significant correlation was observed for IL-32γ and IL1B expression (Fig 6C). Moreover, a significant correlation of IL-32β mRNA expression with IL17 and IL22 mRNA expression was observed (S2 Fig) whereas IL-32α mRNA expression was significantly correlated with IL1A and IL17 mRNA expression (S3 Fig).

Discussion

In the present study, we demonstrated that both L. amazonensis and L. braziliensis induce IL-32 expression in primary human PBMCs. Of interest, L. amazonensis is a stronger inducer of both IL-32γ mRNA and protein than L. braziliensis at least during the first 24 h of PBMC stimulation with Leishmania spp. antigens. Intriguingly, when PBMCs were exposed to both Leishmania species for 7 days, enhanced splicing of IL-32γ mRNA occurred with an increase in IL-32α and IL-32β isoforms expression, resulting in a high amount of IL-32 in the cells. The induction of both IL-32 mRNA and protein reveals to be dependent on several PRRs, namely NOD2, TLR4 and Dectin-1. We showed that genetic variants of the IL32 gene influenced IL-32γ mRNA expression. Moreover, we could demonstrate that these investigated genetic variations influenced the production of innate and acquired Leishmania-induced cytokine production by primary human PBMCs. Of high interest, our data suggest that the IL32 SNP (rs4786370) is associated with susceptibility to ATL. In addition, the IL32 SNP (rs4349147) was associated with the clinical outcome of ATL patients, being more frequent among ML than LCL patients. Lastly, here we demonstrated that the IL-32γ mRNA expression in lesions of ATL patients was positively correlated with the expression of several proinflammatory cytokines, such as IL1A, IFNG, IL17, and IL22. In addition, IL-32α mRNA expression was positively correlated with IL1A and IL17 mRNA expression whereas IL-32β mRNA expression was associated with IL17 and IL22 mRNA expression.

In the present study, it was shown that promastigote antigens are able to induce early expression of IL-32γ in human PBMCs (Figs A and B). In contrast, after 7 days of exposure to both Leishmania species, human PBMCs predominantly expressed IL-32α and IL-32β mRNA (Fig 1C and 1D). In agreement with our findings using promastigotes antigens, previous studies have shown that the infection of THP-1 macrophages with live promastigote forms of L. amazonensis or L. braziliensis as well as the addition of amastigotes forms in PBMCs lead to the early induction of IL-32γ mRNA expression [35,36]. In addition, promastigote antigens from L. amazonensis were able to induce higher levels of IL-32γ than L. braziliensis in PBMCs,
Fig 6. (A) Heatmap showing the expression of selected genes in normal skin versus cutaneous lesions from patients infected with *L. braziliensis* described in [42]. Columns represent individual patients and rows represent individual
confirming the previous results obtained with THP-1 macrophages [36]. In the present study, we have shown that the expression of IL-32 isoforms is dependent on duration of exposure to *Leishmania* antigens, which might reflect the ability of the parasite to modulate IL-32γ splicing as the infection progresses. Moreover, the subset of cells studied, myeloid (24 h) or lymphoid (7 days), may influence the expression of the different IL-32 isoforms. Interestingly, the highest concentrations of intracellular IL-32 protein were seen after 7 days of exposure to *Leishmania* spp. (Fig 1F). Of note, since IL-32 isoforms have different biological properties in regard to the induction of inflammation [46], to determine which IL-32 isoform is being induced for *Leishmania* spp. taking in account the subset of cells and the different stages of disease (early or chronic) might be relevant to understand its relation with the immunopathogenesis of the disease.

Although it was reported previously that *Leishmania* spp. can induced IL-32 in human cells and it is positively associated with cytokine production *in vitro* and *in vivo* [35,36], which receptor is involved in this process is unknown. Using a functional genomics approach, we were able to identify the receptors that are important for *Leishmania* spp. mediated induction of IL-32γ, the most inflammatory isoform of IL-32. Functional genomics revealed to be a powerful approach to identify novel pathways in infectious diseases, such as candidemia, tuberculosis and Lyme disease [47,48]. Of high interest, using a genomics approach and functional validation, we could show that NOD2, TLR4 and Dectin-1 receptors are involved in *Leishmania*-induced IL-32γ expression. Several C-type lectins, such as MR and Mincle have been described as recognition receptors for *Leishmania* [49–51] [12,52]. It is unlikely that MR is involved in the induction of IL-32γ since there were no SNPs identified that modulated the IL-32γ expression (S1B Fig).

Previous data have shown the relevance of IL-32γ for cytokine and microbicidal molecules production during *Leishmania* infections using THP-1 macrophages [36]. In order to demonstrate the role of IL-32 in *Leishmania*-induced cytokine production by primary cells, we described genetic variations within *IL32* that alter IL-32γ mRNA expression and proinflammatory cytokines produced by cells from innate and acquired immunity; thus, we have shown that depending on the *Leishmania* spp., genetic variations in *IL32* lead to functional consequences modulating IL-32γ expression and the production of proinflammatory cytokines in human primary cells (Figs 3,4 and 5). As all cytokines evaluated in this study have been shown to be involved in immunopathogenesis of leishmaniasis [15,16,53] and in the parasite control [54,55], the present data indicate a pivotal role of IL-32 in the induction of cytokine production after *Leishmania* spp. exposure. The results presented here confirm that IL-32γ is a crucial cytokine to control cytokine production induced by *Leishmania* spp. in macrophage cell lines as well as in primary cells.

To investigate whether these genetic variations in *IL32* could be associated with susceptibility or resistance to ATL, we evaluated the differences in genotypes frequencies of ATL patients compared to controls. Genetic variations have been described associated with susceptibility to complicated skin and skin structure infections (cSSSIs) and HIV infections [45,56]. Likewise in our study, we observed an increased frequency of *IL32* rs4786370-CC genotype in controls. This genotype was linked with high IL-32γ and IL-22 induction in PBMCs after exposure to *L.
**IL-32 influences host defense against Leishmania species**

*amazonensis* antigens, which suggest a possible role of IL-32 in decreasing the risk of developing ATL. Despite of *in vitro* cytokine alterations, the other IL32 genetic variants (rs4349147; rs1555001) presented similar frequencies between the groups of ATL patients and controls what could be ascribed due the low number of individuals included in the study. In addition to the low number, other relevant aspect for genetic studies is the presence of a heterogeneity population present in Brazil. Using ancestry-informative DNA polymorphisms in individuals from the four most populous regions of the country, a previous study has unraveled great ancestral diversity between and within different regions of the country [57]. Thus, although the sex-related differences in ATL susceptibility was not addressed in the present study, data from across Brazil show that males are more susceptible to develop cutaneous manifestations of leishmaniasis than females [58]. Since this is first study investigating the role of genetic variations in IL32 associated with susceptibility to ATL, the use of a collective dataset including for genetic associated studies with large number of samples as well as matched asymptomatic and healthy controls, epidemiological variables and host biological factors represent a promising new endeavor within the scientific community in the field of Leishmania research in Brazilian subjects.

After stratifying patients for their IL32 genotype and correlate it with clinical manifestation of the disease, it was observed the allele G of the IL-32 rs4349147 was more frequent in patients with LCL than ML. The G allele was associated with increased levels of IL-32γ, IL-6, IL-1β and IL-22 in PBMCs of healthy individuals exposed to *L. amazonensis* antigens, and with IL-1β and IL-22 to *L. braziliensis* antigens. Thus, these findings suggest that allele G might contribute to the development of the less severe form of the disease conferring protection against ML. Future studies exploring whether the IL-32 rs4349147 is associated with the production of immune mediators are worthwhile in a cohort of ATL patients.

Based on the expression of individual genes coding for immune host defense and being described related with IL-32 expression [29], early and late lesions from *L. braziliensis* skin that are transcriptionally indistinguishable [42] could be clearly separated from normal skin based on mRNA levels. Expression of IL32 and other genes that promote severe inflammation including cytokines, chemokines and also metalloproteinases, which can degrade the extracellular matrix leading to more tissue damage, were higher in *L. braziliensis* lesions. Positive correlations between IL-32 and IL-22 were observed in *L. braziliensis* lesions. IL-22, as well as IL-32, have been described to be important for host defense against microorganisms and antimicrobial peptide secretion [28,29,59].

To investigate the associations between IL-32 isoforms and other proinflammatory cytokines *in vivo*, we evaluated the expression of IL1A, IL1B, IFNγ, IL17, and IL22 in lesions of ATL patients and studied their correlations with IL-32 alpha, beta and gamma. The mRNA of the three IL-32 isoforms, being IL-32γ > IL-32β > IL-32α were detected in the lesions of ATL patients. In the lesions of of ATL patients, IL-32γ mRNA expression was correlated with IL1A, IFNγ, IL17 and IL22. Although IL-32γ is the most prevalent isoform in the lesions of ATL patients (present data; [35]), we also evaluated whether IL-32β and IL-32α isoforms were associated with proinflammatory cytokines in ATL lesions. IL-32β mRNA was correlated with IL17 and IL22; IL-32α with IL1A and IL17 (S1, S2 and S3 Figs). These results suggests that the IL-32γ isoform can be associated with a mixed Th1/Th17 profile whereas IL-32β and IL-32α can be more associated with a Th17 profile. It is known that IL-32γ can induce a mixed Th1/Th17 acquired immune response [33,60]. Previous data has shown that in other inflammatory skin diseases such as Psoriasis and Hydradinitis Superativa, IL-32β was the main isotype that was expressed [61]. Although IL-32β is known to present proinflammatory properties [43], it has been shown that IL-32β induces IL-10 production [62]. IL-32α is regarded as anti-inflammatory member of the IL-32 family which is able to inhibit NK cell activation and JAK/STAT
Thus, in our study all three isoforms are associated with proinflammatory cytokines in ATL, it is possible that IL-32β and IL-32α act as anti-inflammatory mediators in the lesions, being important to decrease the inflammatory process, however, whether IL-32β or IL-32α acts as an anti-inflammatory mediators in lesions of ATL patients is not known at this moment.

In the present study we demonstrated that IL-32γ mRNA expression in the lesions of *Leishmania*-infected patients strongly correlated with cytokines related to skin inflammation, such as IL-17, IL-22 and IL-1α. Of high interest, IL-22 was found to be highly correlated with IL-32γ expression. IL-22 is known as crucial mediator in cutaneous host defense against extracellular microorganisms, however, it seems not relevant to protect against intracellular microorganisms [64]. In addition, IL-22 presents proinflammatory and anti-inflammatory properties, promoting wound healing/repair by activating epithelial cells and fibroblasts [64,65]. In *L. major*- or *L. braziliensis*-infected mice the production of IL-22 decreases the lesion size without any effect on parasite load, indicating that IL-22 is more associated with the control of inflammation and wound healing than with parasite control in cutaneous leishmaniasis [23,66]. The role of IL-17 in ATL has been studied. Several studies suggest that IL-17 can be pathogenic in ML patients [16,20] whereas other suggests a protective role for IL-17 in LCL [67]. In regard to IL-1 family, it has been shown that IL-1α and IL-1β are expressed in ATL lesions caused by *L. braziliensis*. The expression of IL-1β in the lesions of *L. braziliensis*-infected LCL patients has been associated with immunopathology [53]. In opposite to humans, in mouse models, IL-1β has been shown important for protection in C57BL/6 mice infected with *L. braziliensis* or *L. amazonensis* [55]. Thus, the exact mechanism in how IL-32 isoforms modulates the production of proinflammatory cytokines and whether these connections contributes to immunopathology or wound healing remains to be investigated in leishmaniasis.

In conclusion, this study raises the concept of an important role for endogenous IL-32 in modulation of the inflammatory response in humans that influences susceptibility to and progression of localized cutaneous and mucosal leishmaniasis. In ATL, IL-32 is a novel target and may have promising therapeutic potential in the future. However, several aspects of the IL-32 biological function of IL-32 in human immune cells remain elusive. The precise molecular mechanisms mediated by IL-32 in lesions of *Leishmania* patients, including inflammatory pathways and control of parasite load, needs to be elucidated. Moreover, future studies should reveal whether the functional effects of genetic variations in *IL32* observed in human PBMCs are also exerted in the ATL lesions environment.

Supporting information

S1 Table. TaqMan SNP assays.

(S1 Table. TaqMan SNP assays.)

**S1 Fig. PBMCs from healthy donors from the 200FG cohort were stimulated with lysates (50 μg/ mL) of *L. amazonensis* and *L. braziliensis* for 24 hours.** (A) IL-32γ mRNA expression in PBMCs isolated from individuals carrying a frame shift mutation in the NOD2 receptor (rs2066847-leu1007insC n = 3) compared to individuals carrying no mutation (Wt n = 20). The individuals were stratified according with different genotypes of (A) TLR4 rs4986791 (AA n = 26; AG n = 4), TLR2 rs5743708 (GG n = 32; GA n = 2), (B) CLEC7A rs16910526 (AA n = 32; AC n = 1; CC n = 1), CD206 rs1926736 (AA n = 5; AG n = 20; GG n = 18), and IL-32γ gene expression was determined. The data shown are the mean ± SEM of fold change in IL-32γ expression induced by *Leishmania* spp. normalized to RPMI control. (S1 Fig. PBMCs from healthy donors from the 200FG cohort were stimulated with lysates (50 μg/ mL) of *L. amazonensis* and *L. braziliensis* for 24 hours.)
S2 Fig. Correlation of IL-32β with IL1B, IL1A, IFNG, IL17 and IL22 gene expression in skin biopsies of ATL patients. The data shown are log2 of Relative expression adjusted for beta-2 microglobulin expression (n = 56).

(TIFF)

S3 Fig. Correlation of IL-32α with IL1B, IL1A, IFNG, IL17 and IL22 gene expression in skin biopsies of ATL patients. The data shown are log2 of Relative expression adjusted for beta-2 microglobulin expression (n = 56).

(TIFF)

Acknowledgments
We would like to thank H.M. da Rocha Sobrinho for the help collecting individuals to build the cohort of healthy Brazilian individuals.

Author Contributions
Conceptualization: Mihai G. Netea, Fátima Ribeiro-Dias, Leo A. B. Joosten.
Data curation: Jeâssica Cristina dos Santos, Valéria Bernadete Leite Quixabeira.
Formal analysis: Jeâssica Cristina dos Santos, Valéria Bernadete Leite Quixabeira, Muriel Vilela Teodoro Silva, Michelle S. M. A. Damen, Kiki Schraa, Martin Jaeger, Marije Oosting.
Funding acquisition: Mihai G. Netea, Fátima Ribeiro-Dias, Leo A. B. Joosten.
Investigation: Jeâssica Cristina dos Santos, Valéria Bernadete Leite Quixabeira.
Methodology: Jeâssica Cristina dos Santos, Valéria Bernadete Leite Quixabeira, Muriel Vilela Teodoro Silva, Michelle S. M. A. Damen, Kiki Schraa, Martin Jaeger, Marije Oosting, Miriam Leandro Dorta, Sebastião Alves Pinto, Fernanda Bugalho Duarte.
Project administration: Fátima Ribeiro-Dias, Leo A. B. Joosten.
Resources: Mihai G. Netea, Fátima Ribeiro-Dias, Leo A. B. Joosten.
Software: Jeâssica Cristina dos Santos, Valéria Bernadete Leite Quixabeira.
Supervision: Fátima Ribeiro-Dias, Leo A. B. Joosten.
Validation: Jeâssica Cristina dos Santos, Valéria Bernadete Leite Quixabeira.
Visualization: Jeâssica Cristina dos Santos, Valéria Bernadete Leite Quixabeira.
Writing – original draft: Jeâssica Cristina dos Santos, Valéria Bernadete Leite Quixabeira.
Writing – review & editing: Jeâssica Cristina dos Santos, Marije Oosting, Samuel T. Keating, Miriam Leandro Dorta, Ledice Inácia de Araújo Pereira, Mihai G. Netea, Fátima Ribeiro-Dias, Leo A. B. Joosten.

References
1. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. Lancet Infect Dis. 2007; 7(9):581–96. https://doi.org/10.1016/S1473-3099(07)70209-8 PMID: 17714672
2. Silveira FT, Lainson R, Corbett CE. Clinical and immunopathological spectrum of American cutaneous leishmaniasis with special reference to the disease in Amazonian Brazil: a review. Mem Inst Oswaldo Cruz. 2004; 99(3):239–51. https://doi.org/10.1590/s0074-02762004000300001 PMID: 15273794
3. Goto H, Lauletta Lindoso JA. Cutaneous and mucocutaneous leishmaniasis. Infect Dis Clin North Am. 2012; 26(2):283–307. https://doi.org/10.1016/j.idc.2012.03.001 PMID: 22632640
4. Lessa HA, Machado P, Lima F, Cruz AA, Bacellar O, Guerreiro J, et al. Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg. 2001; 65(2):87–9. https://doi.org/10.4269/ajtmh.2001.65.87 PMID: 11508396

5. Azeredo-Coutinho RB, Conceicao-Silva F, Schubach A, Cupolillo E, Quintella LP, Madeira MF, et al. First report of diffuse cutaneous leishmaniasis and Leishmania amazonensis infection in Rio de Janeiro State, Brazil. Trans R Soc Trop Med Hyg. 2007; 101(7):735–7. https://doi.org/10.1016/j.trstmh.2007.01.005 PMID: 17368698

6. Pereira LI, Dorta ML, Pereira AJ, Bastos RP, Oliveira MA, Pinto SA, et al. Increase of NK cells and proinflammatory monocytes are associated with the clinical improvement of diffuse cutaneous leishmaniasis after immunochemotherapy with BCG/Leishmania antigens. Am J Trop Med Hyg. 2009; 81(3):378–83. PMID: 19706899

7. Peters NC, Sacks DL. The impact of vector-mediated neutrophil recruitment on cutaneous leishmaniasis. Cell Microbiol. 2009; 11(9):1290–6. https://doi.org/10.1111/j.1462-5822.2009.01348.x PMID: 19545276

8. Romano A, Carneiro MBH, Doria NA, Roma EH, Ribeiro-Gomes FL, Inbar E, et al. Divergent roles for Ly6C+CCR2+CX3CR1+ inflammatory monocytes during primary or secondary infection of the skin with the intra-phagosomal pathogen Leishmania major. PLoS Pathog. 2017; 13(6):e1006479. https://doi.org/10.1371/journal.ppat.1006479 PMID: 28666021

9. de Assis RR, Ibraim IC, Nogueira PM, Soares RP, Turco SJ. Glycoconjugates in New World species of Leishmania: polymorphisms in lipophosphoglycan and glycoinositolphospholipids and interaction with hosts. Biochim Biophys Acta. 2012; 1820(9):1354–65. https://doi.org/10.1016/j.bbagen.2011.11.001 PMID: 22993608

10. Ibraim IC, de Assis RR, Pessoa NL, Campos MA, Melo MN, Turco SJ, et al. Two biochemically distinct lipophosphoglycans from Leishmania braziliensis and Leishmania infantum trigger different innate immune responses in murine macrophages. Parasit Vectors. 2013; 6:54. https://doi.org/10.1186/1756-3305-6-54 PMID: 23497381

11. Nogueira PM, Assis RR, Torrecilha AC, Saraiva EM, Pessoa NL, Campos MA, et al. Lipophosphoglycans from Leishmania amazonensis Strains Display Immunomodulatory Properties via TLR4 and Do Not Affect Sand Fly Infection. PLoS Negl Trop Dis. 2016; 10(8):e0004848. https://doi.org/10.1371/journal.pntd.0004848 PMID: 27508930

12. Dos Santos JC, Damen M, Oosting M, de Jong DJ, Heinhuis B, Gomes RS, et al. The NOD2 receptor is crucial for immune responses towards New World Leishmania species. Sci Rep. 2017; 7(1):15219. https://doi.org/10.1038/s41598-017-15412-7 PMID: 29123157

13. Lee SH, Charmoy M, Romano A, Paun A, Chaves MM, Cope FO, et al. Mannose receptor high, M2 dermal macrophages mediate nonhealing Leishmania major infection in a Th1 immune environment. J Exp Med. 2018; 215(1):357–75. https://doi.org/10.1084/jem.20171389 PMID: 29247046

14. Rojas-Bernabe A, Garcia-Hernandez O, Maldonado-Bernal C, Delegado-Dominguez J, Ortega E, Gutierrez-Kobeh L, et al. Leishmania mexicana lipophosphoglycan activates ERK and p38 MAP kinase and induces production of proinflammatory cytokines in human macrophages through TLR2 and TLR4. Parasitology. 2014; 141(6):788–800. https://doi.org/10.1017/S0031182013002187 PMID: 24512642

15. Antonelli LR, Dutra WO, Almeida RP, Bacellar O, Carvalho EM, Gollob KJ. Activated inflammatory T cells correlate with lesion size in human cutaneous leishmaniasis. Immunol Lett. 2005; 101(2):226–30. https://doi.org/10.1016/j.imlet.2005.06.004 PMID: 16083969

16. Boaventura VS, Santos CS, Cardoso CR, de Andrade J, Dos Santos WL, Clanciero J, et al. Human mucosal leishmaniasis: neutrophils infiltrate areas of tissue damage that express high levels of Th17-related cytokines. Eur J Immunol. 2010; 40(10):2830–6. https://doi.org/10.1002/eji.200940115 PMID: 20812234

17. Maretli-Mira AC, Bittner J, Oliveira-Neto MP, Liu M, Kang D, Li H, et al. Transcriptome patterns from primary cutaneous Leishmania braziliensis infections associate with eventual development of mucosal disease in humans. PLoS Negl Trop Dis. 2012; 6(9):e1816. https://doi.org/10.1371/journal.pntd.0001816 PMID: 23029578

18. Novais FO, Scott P. CD8+ T cells in cutaneous leishmaniasis: the good, the bad, and the ugly. Semin Immunopathol. 2015; 37(3):251–9. https://doi.org/10.1007/s00281-015-0475-7 PMID: 25800274

19. Gomes-Silva A, de Cassia Bittar R, Dos Santos Nogueira R, Amato VS, da Silva Mattos M, Oliveira-Neto MP, et al. Can interferon-gamma and interleukin-10 balance be associated with severity of human Leishmania (Viannia) braziliensis infection? Clin Exp Immunol. 2007; 149(3):440–4. https://doi.org/10.1111/j.1365-2249.2007.03436.x PMID: 17614975

20. Gonzalez-Lombana C, Gimblet C, Bacellar O, Oliveira WW, Passos S, Carvalho LP, et al. IL-17 mediates immunopathology in the absence of IL-10 following Leishmania major infection. PLoS Pathog. 2013; 9(3):e1003243. https://doi.org/10.1371/journal.ppat.1003243 PMID: 23555256
21. Sa SM, Valdez PA, Wu J, Jung K, Zhong F, Hall L, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol. 2007; 178(4):2229–40. https://doi.org/10.4049/jimmunol.178.4.2229 PMID: 17277128

22. Wolk K, Kunz S, Asadullah K, Sabat R. Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol. 2002; 168(11):5397–402. https://doi.org/10.4049/jimmunol.168.11.5397 PMID: 12023331

23. Gimblet C, Loesche MA, Carvalho L, Carvalho EM, Grice EA, Artis D, et al. IL-22 Protects against Tissue Damage during Cutaneous Leishmaniasis. PLoS One. 2015; 10(8):e0134698. https://doi.org/10.1371/journal.pone.0134698 PMID: 26285207

24. Bai X, Shang S, Henao-Tamayo M, Basaraba RJ, Ovrutsky AR, Matsuda JL, et al. Human IL-32 expression protects mice against a hypervirulent strain of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2015; 112(16):5111–6. https://doi.org/10.1073/pnas.1424302112 PMID: 25820174

25. Heinhuis B, Koenders MI, van Riel PL, van de Loo FA, Dinarello CA, Netea MG, et al. Tumour necrosis factor alpha-driven IL-32 expression in rheumatoid arthritis synovial tissue amplifies an inflammatory cascade. Ann Rheum Dis. 2011; 70(4):660–7. https://doi.org/10.1136/ard.2010.139196 PMID: 21187297

26. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity. 2005; 22(1):131–42. https://doi.org/10.1016/j.immuni.2004.12.003 PMID: 15664165

27. Montoya D, Inkeles MS, Liu PT, Realegeno S, Teles RM, Vaidya P, et al. IL-32 is a molecular marker of a host defense network in human tuberculosis. Sci Transl Med. 2014; 6(250):250ra114. https://doi.org/10.1126/scitranslmed.3009546 PMID: 25143364

28. Dos Santos JC, Damen M, Joosten LAB, Ribeiro-Dias F. Interleukin-32: an endogenous danger signal or master regulator of intracellular pathogen infections-Focus on leishmaniases. Semin Immunol. 2018.

29. Kang JW, Park YS, Lee DH, Kim MS, Bak Y, Ham SY, et al. Interaction network mapping among IL-32 isoforms. Biochimie. 2014; 101:4296–51. https://doi.org/10.1016/j.biochimi.2014.01.013 PMID: 24472437

30. Hong J, Bae S, Yang K, Yoon D, Bai X, Chan ED, et al. Suppressing IL-32 in monocytes impairs the induction of the proinflammatory cytokines TNFalpha and IL-1beta. Cytokine. 2010; 49(2):171–6. https://doi.org/10.1016/j.cyto.2009.10.003 PMID: 19880327

31. Netea MG, Azam T, Ferwerda G, Girardin SE, Walsh M, Park JS, et al. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci U S A. 2005; 102(45):16309–14. https://doi.org/10.1073/pnas.0508237102 PMID: 16260731

32. Jung MY, Son MH, Kim SH, Cho D, Kim TS. IL-32gamma induces the maturation of dendritic cells with Th1- and Th17-polarizing ability through enhanced IL-12 and IL-6 production. J Immunol. 2011; 186(12):6848–59. https://doi.org/10.4049/jimmunol.1003996 PMID: 21551364

33. Kim DH, Park ES, Lee AR, Park S, Park YK, Ahn SH, et al. Intracellular interleukin-32gamma mediates antiviral activity of cytokines against hepatitis B virus. Nat Commun. 2018; 9(1):3284. https://doi.org/10.1038/s41467-018-05782-5 PMID: 30115930

34. Galdino H Jr., Maldaner AE, Pessoni LL, Soriani FM, Pereira LI, Pinto SA, et al. Interleukin 32gamma (IL-32gamma) is highly expressed in cutaneous and mucosal lesions of American Tegumentary Leishmaniasis patients: association with tumor necrosis factor (TNF) and IL-10. PLoS Negl Trop Dis. 2014; 8(7):e0003195.
39. Volpini AC, Passos VM, Oliveira GC, Romana AJ. PCR-RFLP to identify Leishmania (Viannia) braziliensis and L. (Leishmania) amazonensis causing American cutaneous leishmaniasis. Acta Trop. 2004; 90(1):31–7. https://doi.org/10.1016/j.actatropica.2003.10.008 PMID: 14739020

40. Popa C, Abdollahi-Roodsaz S, Joosten LA, Takahashi N, Sprong T, Matera G, et al. Bartonella quintana lipopolysaccharide is a natural antagonist of Toll-like receptor 4. Infect Immun. 2007; 75(10):4831–7. https://doi.org/10.1128/IAI.2007-037 PMID: 17606598

41. Li Y, Oosting M, Smeekens SP, Jaeger M, Aguirre-Gamboa R, Le KTT, et al. A Functional Genomics Approach to Understand Variation in Cytokine Production in Humans. Cell. 2016; 167(4):1099–110 e14. https://doi.org/10.1016/j.cell.2016.10.017 PMID: 27814507

42. Novais FO, Carvalho LP, Passos S, Roos DS, Carvalho EM, Scott P, et al. Genomic profiling of human Leishmania braziliensis lesions identifies transcriptional modules associated with cutaneous immunopathology. J Invest Dermatol. 2015; 135(1):94–101. https://doi.org/10.1038/jid.2014.305 PMID: 25036052

43. Heinhuis B, Plantinga TS, Semango G, Kusters B, Netea MG, Dinarello CA, et al. Alternatively spliced isoforms of IL-32 differentially influence cell death pathways in cancer cell lines. Carcinogenesis. 2016; 37(2):197–205. https://doi.org/10.1093/carcin/bgv172 PMID: 26678222

44. Damen M, Dos Santos JC, Hermesen R, Adam van der Vliet J, Netea MG, Riksen NP, et al. Interleukin-32 upregulates the expression of ABCA1 and ABCG1 resulting in reduced intracellular lipid concentrations in primary human hepatocytes. Atherosclerosis. 2018; 271:193–202. https://doi.org/10.1016/j.atherosclerosis.2018.02.027 PMID: 29524962

45. Palstra RJ, de Crignis E, Roling MD, van Staven T, Kan TW, van Ijcken W, et al. Allele-specific long-distance regulation dictates IL-32 isoform switching and mediates susceptibility to HIV-1. Sci Adv. 2018; 4(2):e1701729. https://doi.org/10.1126/sciadv.1701729 PMID: 29507875

46. Heinhuis B, Plantinga TS, Semango G, Kusters B, Netea MG, Dinarello CA, et al. Alternately spliced IL-32 promotes and inhibits cell death. Proc Natl Acad Sci U S A. 2021; 118(14):e20232242. https://doi.org/10.1073/pnas.20232242118 PMID: 33742932

47. Li Y, Oosting M, Deelen P, Ricano-Ponce I, Smeekens SP, Jaeger M, et al. Inter-individual variability and genetic influences on cytokine responses to bacteria and fungi. Nat Med. 2016; 22(8):952–60. https://doi.org/10.1038/nm.4139 PMID: 27376574

48. Stappers MH, Thys Y, Oosting M, Plantinga TS, Ioana M, Reimnitz P, et al. Polymorphisms in cytokine genes IL6, TNF, IL10, IL17A and IFNG influence susceptibility to complicated skin and skin structure infections. Eur J Clin Microbiol Infect Dis. 2014; 33(12):2267–74. https://doi.org/10.1007/s10096-014-2201-0 PMID: 25022448
57. Pena SD, Di Pietro G, Fuchshuber-Moraes M, Genro JP, Hutz MH, Kehdy Fde S, et al. The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected. PLoS One. 2011; 6(2):e17063. https://doi.org/10.1371/journal.pone.0017063 PMID: 21359226

58. Lockard RD, Wilson ME, Rodriguez NE. Sex-Related Differences in Immune Response and Symptomatic Manifestations to Infection with Leishmania Species. J Immunol Res. 2019; 2019:4103819. https://doi.org/10.1155/2019/4103819 PMID: 30756088

59. Bichele R, Karner J, Truusalu K, Smidt I, Mandar R, Conti HR, et al. IL-22 neutralizing autoantibodies impair fungal clearance in murine oropharyngeal candidiasis model. Eur J Immunol. 2018; 48(3):464–70. https://doi.org/10.1002/eji.201747209 PMID: 29150834

60. Gomes RS, Silva MVT, Dos Santos JC, van Linge C, Reis JM, Teixeira MM, et al. Human Interleukin-32gamma Plays a Protective Role in an Experimental Model of Visceral Leishmaniasis in Mice. Infect Immun. 2018; 86(5).

61. Al-Shobaili HA, Rasheed Z. Elevated Gene Expression of Interleukin-32 Isoforms Alpha, Beta, Gamma, and Delta in the Peripheral Blood of Chronic Psoriatic Patients. Diseases. 2018; 6(1).

62. Kang JW, Park YS, Kim MS, Lee DH, Bak Y, Ham SY, et al. Interleukin (IL)-32beta-mediated CCAAT/ enhancer-binding protein alpha (C/EBPalpha) phosphorylation by protein kinase Cdelta (PKCdelta) abrogates the inhibitory effect of C/EBPalpha on IL-10 production. J Biol Chem. 2013; 288(33):23650–8. https://doi.org/10.1074/jbc.M113.465575 PMID: 23814099

63. Gorvel L, Korenfeld D, Tung T, Klechevsky E. Dendritic Cell-Derived IL-32alpha: A Novel Inhibitory Cytokine of NK Cell Function. J Immunol. 2017; 199(4):1290–300. https://doi.org/10.4049/jimmunol.1601477 PMID: 28701509

64. Wilson MS, Feng CG, Barber DL, Yarovinsky F, Cheever AW, Sher A, et al. Redundant and pathogenic roles for IL-22 in mycobacterial, protozoan, and helminth infections. J Immunol. 2010; 184(6):4378–90. https://doi.org/10.4049/jimmunol.0903416 PMID: 20220096

65. Alabbas SY, Begun J, Florin TH, Oancea I. The role of IL-22 in the resolution of sterile and nonsterile inflammation. Clin Transl Immunology. 2018; 7(4):e1017. https://doi.org/10.1002/cti2.1017 PMID: 29713472

66. Brosch S, Dietze-Schwonberg K, Lopez Kostka S, Lorenz B, Haak S, Becher B, et al. Disease control in cutaneous leishmaniasis is independent of IL-22. J Invest Dermatol. 2015; 135(1):308–11. https://doi.org/10.1038/jid.2014.282 PMID: 24999596

67. Novoa R, Bacellar O, Nascimento M, Cardoso TM, Ramasawmy R, Oliveira WN, et al. IL-17 and Regulatory Cytokines (IL-10 and IL-27) in L. braziliensis Infection. Parasite Immunol. 2011; 33(2):132–6. https://doi.org/10.1111/j.1365-3024.2010.01256.x PMID: 21226726